Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + irbesartan
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Atorvastatin + irbesartan** is an oral fixed-dose combination of two small molecules marketed in South Korea as **Rovelito**. It combines atorvastatin, an HMG-CoA reductase inhibitor that lowers low-density lipoprotein cholesterol, with irbesartan, a selective angiotensin II type 1 receptor antagonist that lowers blood pressure. Developed by Hanmi Pharmaceutical for patients with concomitant hypertension and hypercholesterolemia, the combination was evaluated in Phase III and Phase IV studies and is intended to simplify treatment of these coexisting cardiovascular risk factors.
- Brand names
- Rovelito
- Other names
- irbesartan + atorvastatinirbesartan-atorvastatinirbesartan/atorvastatin
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + irbesartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + irbesartan.